Background: Tablet splitting is commonly used in clinical practice as a way to attain a desired drug dose and/or reduce its side effects, particularly among paediatricians and psychiatrists. However, uneven tablet scoring can lead to significant fluctuations of the administered doses, where subpotency or superpotency of
drugs might harm the patients. The aim of this study was to evaluate the influence
of tablet splitting on dose uniformity of diazepam by the utilisation of Ph. Eur. 9.0
and FDA recommendations.
Methods: Mass variation of whole and half-tablets in parallel with the determination of their content uniformity were performed according to the pharmacopoeial
methods. The weight loss after tablet splitting was assessed by employing FDA
guidelines. It was also investigated if tablet splitting influenced the in vitro dissolution properties of diazepam tablets.
Results: Diazepam whole tablets fulfilled the pharmacopoeial requirements in
regard to all the investigated properties. The weight uniformity of scored diazepam tablets ranged from 63.80% to 122.55% label claim. The losses of mass after
splitting diazepam tablets were 5.71%. Despite the average content of diazepam
in half-tablets was found to be 104.24% label claim, the requirements of Ph. Eur.
were not fulfilled. Diazepam content in half-tablets ranged from 0.76 mg to 1.21
mg, thus, patients might receive doses that vary by as much as 45%. However,
after weight adjustment, diazepam content in each of the tested half-tablets was
in the range of 85-115% of the average drug content meeting the Ph. Eur. criteria.
Dissolution profiles of whole and half-tablets were found to be similar, following
the Hixson-Crowell kinetic model.
Conclusion: According to the results, splitting of diazepam tablets greatly influenced the drug content in the obtained parts, ie the dose accuracy was fully dependent of the ability to score the tablet into exactly equal halves.
